Apigenin for Insomnia
There is not enough evidence to say whether isolated apigenin helps with insomnia. No human trial has tested the purified compound for sleep; the few existing studies used whole chamomile extract, which is not the same thing.
Why this grade7-layer evidence engine
This claim is graded Unverified (Insufficient Evidence) because there are zero human randomized trials of isolated apigenin for insomnia. Every clinical signal comes from whole-herb chamomile extract, in which apigenin is only about 1.2% alongside many other flavonoids and terpenes, so those results cannot be validly attributed to the purified compound.
The two proxy trials are also weak and inconsistent. Zick 2011 (PMID 21939549), a double-blind pilot in 34 adults with chronic primary insomnia, found only small, non-significant improvements in sleep latency and total sleep time versus placebo. Adib-Hajbaghery 2017 (PMID 29154054), in 60 nursing-home elders, reported better sleep-quality scores, but it was single-blind with a no-treatment comparator, carrying a high risk of bias.
Health authorities offer no support. NIH/NCCIH states there isn't enough evidence that chamomile helps any condition, and Cleveland Clinic notes the sleep research is limited; the FDA, EFSA, NHS and WHO do not address isolated apigenin at all. A sleep-medicine guideline (AASM) even advises against herbal/OTC sleep aids as a class. A possible drug-interaction concern (CYP enzyme inhibition) adds further caution.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.384
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — D 級條件未達 (需 E1-E3 negative；實際 E6)
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status